WaveMan · Company
BLGO · Biolargo, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BLGO Biolargo (BLGO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Chemicals & allied products · CIK 0000880242
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-56.3%
XBRL, annual
Net margin
-195.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.1M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$7.8M
FY Dec 2024$17.8M
FY Dec 2023$12.2M
FY Dec 2022$5.9M
FY Dec 2021$2.5M
Jun 2026$1.2M
Mar 2026$1.1M
Dec 2025$617.0K
Sep 2025$1.1M
Jun 2025$2.8M
Mar 2025$3.3M
Dec 2024$3.7M
Sep 2024$4.4M
At each fiscal year end
Single quarter
Net margin, TTM
-460.2%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-195.6%
FY Dec 2024-24.4%
FY Dec 2023-38.0%
FY Dec 2022-87.2%
FY Dec 2021-272.0%
Jun 2026-320.5%
Mar 2026-305.4%
Dec 2025-671.3%
Sep 2025-656.8%
Jun 2025-67.8%
Mar 2025-58.8%
Dec 2024-47.4%
Sep 2024-24.4%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$10.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025-$8.3M
FY Dec 2024-$4.4M
FY Dec 2023-$2.8M
FY Dec 2022-$3.0M
FY Dec 2021-$4.0M
Jun 2026-$3.2M
Mar 2026-$2.9M
Dec 2025-$1.6M
Sep 2025-$2.8M
Jun 2025-$2.1M
Mar 2025-$1.8M
Dec 2024-$1.9M
Sep 2024-$1.7M
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 20250.51x
FY Dec 20240.12x
FY Dec 20230.05x
FY Dec 20220.07x
FY Dec 20210.11x
Jun 2026n/a
Mar 20261.16x
Dec 20250.51x
Sep 20250.16x
Jun 20250.12x
Mar 20250.14x
Dec 20240.12x
Sep 20240.03x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-4.96x
TTM operating cash flow over LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion)
History
FY Dec 2025-3.99x
FY Dec 2024-2.97x
FY Dec 2023-6.66x
FY Dec 2022-8.20x
FY Dec 2021-7.97x
Jun 2026-4.96x
Mar 2026-4.51x
Dec 2025-3.99x
Sep 2025-7.99x
Jun 2025-6.94x
Mar 2025-5.11x
Dec 2024-2.97x
Sep 2024-5.25x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-544.4%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-235.6%
FY Dec 2024-55.4%
FY Dec 2023-79.3%
FY Dec 2022-107.7%
FY Dec 2021-162.0%
Jun 2026-544.4%
Mar 2026-354.9%
Dec 2025-235.6%
Sep 2025-168.6%
Jun 2025-89.4%
Mar 2025-69.9%
Dec 2024-55.4%
Sep 2024-46.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-196.1%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-161.4%
FY Dec 2024-46.4%
FY Dec 2023-71.2%
FY Dec 2022-130.2%
FY Dec 2021-173.1%
Jun 2026-196.1%
Mar 2026-174.8%
Dec 2025-161.4%
Sep 2025-131.5%
Jun 2025-58.5%
Mar 2025-54.0%
Dec 2024-46.4%
Sep 2024-43.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-351.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-267.3%
FY Dec 2024-64.8%
FY Dec 2023-104.3%
FY Dec 2022-218.7%
FY Dec 2021-445.0%
Jun 2026-351.1%
Mar 2026-300.8%
Dec 2025-267.3%
Sep 2025-194.9%
Jun 2025-82.0%
Mar 2025-80.1%
Dec 2024-64.8%
Sep 2024-62.5%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$26.4M
market value at close 2026-10-09 on 2026-08-12 shares, plus LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion), minus cash 2026-06-30
History
FY Dec 2025$54.7M
FY Dec 2024$54.8M
FY Dec 2023$46.0M
FY Dec 2022$50.8M
FY Dec 2021$53.7M
Jun 2026$35.2M
Mar 2026$49.1M
Dec 2025$54.7M
Sep 2025$49.1M
Jun 2025$61.2M
Mar 2025$82.9M
Dec 2024$54.8M
Sep 2024$65.5M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-39.8%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025-14.8%
FY Dec 2024-7.8%
FY Dec 2023-5.8%
FY Dec 2022-5.8%
FY Dec 2021-7.3%
Jun 2026-29.9%
Mar 2026-18.5%
Dec 2025-14.8%
Sep 2025-16.4%
Jun 2025-11.8%
Mar 2025-7.0%
Dec 2024-7.8%
Sep 2024-3.9%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

BLGO Stock Sonar score 4/7 axes

Find similar shapesCompare

BLGO ranks highest on risk and compliance (82nd percentile) and financial health (29th), and lowest on profitability (8th), among Pharma & Biotech peers.

Profitability
8
Inputs
  • Return on equity-544.4% · 7 pct, sector of 546
  • Return on assets-196.1% · 11 pct, sector of 693
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-351.1% · 5 pct, sector of 578
Financial health
29
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-4.96x · 29 pct, sector of 371
Growth
19
Inputs
  • Revenue growth, YoY-56.3% · 19 pct, sector of 506
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
82
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 814
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.8% · 65 pct, sector of 512
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-56.3% year over year
below 81% of Pharma & Biotech
Margin
-195.6% net margin
below 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BLGO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-52.5%12M
-59%-33%-8%+18%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Biolargo insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BIOLARGO, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns BLGO: institutional holders (13F)

13F holdings, latest reported quarter
FIRST AMERICAN TRUST, FSB
117,838 sh
$13.4K

Congress trades in BLGO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BLGO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$318.0K
$318.0K
$265.5K
-10%
n/a
2023
$316.6K
$299.4K
$214.9K
-21%
n/a
2022
$456.0K
$313.6K
$226.5K
-8%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$7.8M$17.8M$12.2M$5.9M
Gross profit$3.4M$7.9M$6.2M$2.9M
Operating income$-14.9M$-4.3M$-4.6M$-5.4M
Net income$-15.2M$-4.3M$-4.6M$-5.1M
Operating cash flow$-8.3M$-3.2M$-2.4M$-2.8M
Cash$3.9M$3.5M$3.5M$1.9M
Long-term debt$2.1M$1.1M$289.0K$237.0K
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies